Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01147484
What this trial is testing

Foretinib in Patients With Recurrent/Metastatic Breast Cancer

Who this might be right for
Recurrent Breast Cancer
NCIC Clinical Trials Group 47
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Early research (Phase 1)Looking for participantsNCT06910657
What this trial is testing

IDOV-Immune for Advanced Solid Tumors

Who this might be right for
Colorectal CancerPancreatic CancerMelanoma+13 more
ViroMissile, Inc. 78
Testing effectiveness (Phase 2)Study completedNCT01491737
What this trial is testing

Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 258
Not applicableStudy completedNCT07148505
What this trial is testing

Real-world Outcomes Among Patients Treated With Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 373
Early research (Phase 1)Looking for participantsNCT05005403
What this trial is testing

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Who this might be right for
Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMicro Satellite Stable Colorectal Cancer+4 more
AbbVie
Early research (Phase 1)Study completedNCT03199586
What this trial is testing

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Who this might be right for
Breast CancerPancreas CancerProstate Cancer+6 more
Novita Pharmaceuticals, Inc. 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751
What this trial is testing

Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Not applicableStudy completedNCT01782651
What this trial is testing

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 1
Testing effectiveness (Phase 2)Study completedNCT02748213
What this trial is testing

Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Testing effectiveness (Phase 2)Study completedNCT02924883
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 202
Not applicableUnknownNCT05734950
What this trial is testing

Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

Who this might be right for
Breast Cancer Female
Royal Marsden NHS Foundation Trust 100
Testing effectiveness (Phase 2)Study completedNCT01134250
What this trial is testing

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Who this might be right for
Solid TumorBreast CancerMetastatic Melanoma+1 more
Philogen S.p.A. 48
Very early researchNot Yet RecruitingNCT07639970
What this trial is testing

Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors

Who this might be right for
Breast CancerHead and Neck Cancer (H&N)Pancreatic Cancer+1 more
Hua Pang 20
Testing effectiveness (Phase 2)Ended earlyNCT04720729
What this trial is testing

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

Who this might be right for
HER2-negative Metastatic Breast Cancer
Institut Curie 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04739761
What this trial is testing

T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 506
Not applicableStudy completedNCT01959386
What this trial is testing

Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 1,006
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06481956
What this trial is testing

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Who this might be right for
HER2-positive Advanced Breast Cancer
Zheng Yabing 40
Next Page
694